Differential effects of nonsteroidal antiinflammatory drugs on the IL-1 altered expression of plasminogen activators and plasminogen activator inhibitor-1 by articular chondrocytes

Inflammation Research

Volumn 51, Issue 8, 2002, Pages 427-433

  Sadowski, T ^a,b   Steinmeyer, J ^a,c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

NSAD; Osteoarthritis; Plasminogen activator inhibitor 1; Tissue type plasminogen activator; Urokinase

Indexed keywords

INDOMETACIN; INTERLEUKIN 1; INTERLEUKIN 1ALPHA; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIAPROFENIC ACID; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CONCENTRATION RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME RELEASE; EXTRACELLULAR MATRIX; NONHUMAN; PROTEIN EXPRESSION;

EID: 0036678058     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00000325     Document Type: Article

References (40)

1. Purification and cloning of aggrecanase-1: A member of the ADAMTS family of proteins
2. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family
3. Biochemical and biological aspects of the plasminogen activator system
4. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma
5. The placental type plasminogen activator inhibitor, PAI-2
6. Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes
7. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor 2
8. Plasmin degradation of cartilage proteoglycan
9. Endogenous activation of latent collagenase by rheumatoid synovial cells
10. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes
11. 2-macroglobulin and TIMP
12. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis
13. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage
14. Exacerbation of antigen-induced arthritis in urokinase-deficient mice
15. Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis
16. Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium
17. Control of the chondrocyte fibrinolytic balance by the drug piroxicam: Relevance to the osteoarthritic process
18. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts
19. Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis
20. Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes
21. Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1
22. Angiotensin II regulates the expression of plasminogen activator inhibitor in cultured endothelial cells
23. The influence of tissue cross-talking on OA progression: Role of nonsteroidal antiinflammatory drugs
24. The effects of NSAID on the matrix of human articular cartilages
25. Interleukin 1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes
26. 2 receptor subtype in bovine chondrocytes in culture
27. Regulation of cyclooxgenase-2 expression in bovine chondrocytes in culture by interleukin 1alpha, tumor necrosis factor-alpha, glucocorticoids, and 17beta-estradiol
28. Effect of anti-inflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes
29. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos
30. A DNA motif related to the cAMP-responsive element and an exon-located activator protein-2 binding site in the human tissue-type plasminogen activator gene promoter cooperate in basal expression and convey activation by phorbol esters
31. The correlation between plasminogen activator activity and thymidine incorporation in mouse bone marrow-derived macrophages. Opposing actions of colony-stimulating factor, phorbol myristate acetate, dexamethasone and prostaglandin E
32. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases
33. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis
34. Kinetics of salicylates in blood and joint fluid
35. Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations
36. Clinical pharmacokinetics of tiaprofenic acid and its enantiomers
37. Pharmacological influence on the activity of plasmin and plasminogen activators in vitro
38. Cartilage synthesizes the serine protease inhibitor PAI-1: Support for the involvement of serine proteases in cartilage remodeling
39. 2: Mediation by protein kinase A and role of interleukin-1
40. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin